13.48
-0.42 (-3.02%)
| Penutupan Terdahulu | 13.90 |
| Buka | 13.50 |
| Jumlah Dagangan | 2,395,931 |
| Purata Dagangan (3B) | 7,657,886 |
| Modal Pasaran | 11,279,472,640 |
| Harga / Pendapatan (P/E TTM) | 18.47 |
| Harga / Jualan (P/S) | 11.99 |
| Harga / Buku (P/B) | 5.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2025 - 1 Sep 2025 |
| Margin Keuntungan | 7.29% |
| Margin Operasi (TTM) | -24.24% |
| EPS Cair (TTM) | 0.030 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -70.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -93.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.45% |
| Nisbah Semasa (MRQ) | 2.82 |
| Aliran Tunai Operasi (OCF TTM) | 30.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 26.05 M |
| Pulangan Atas Aset (ROA TTM) | -1.04% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | HBM HOLDINGS-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 15.91% |
| % Dimiliki oleh Institusi | 7.85% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |